The content on this site is intended for healthcare professionals only

For the latest ecancer COVID-19 resources, click on this link

PSA/Prostate screening

Bookmark and Share

2009 ASCO Annual Meeting

29 May - 2 Jun 2009

Please rate this video

The information in this video was of interest to me

The information in this video is likely to improve my clinical practice or research

I would recommend this video to my colleagues
Published: 25 Jun 2009
Views: 13652
Rating:
Save
Dr. Otis W. Brawley - Chief Medical Officer, ASCO
Prostate cancer screening studies and ASCO 2009

Related Videos

Advance Prostate Cancer Consensus Conference 2021: Report
Prof Silke Gillessen and Prof Aurelius Omlin
Advance Prostate Cancer Consensus Conference 2021: Report ( Prof Silke Gillessen and Prof Aurelius Omlin )
29 Apr 2022
ASCO GU 2022: Prostate roundup
Prof Eleni Efstathiou, Prof Axel Merseburger and Dr Neal Shore
ASCO GU 2022: Prostate roundup ( Prof Eleni Efstathiou, Prof Axel Merseburger and Dr Neal Shore )
20 Apr 2022
Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid ...
Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia
Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid tumours ( Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia )
14 Apr 2022
PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/...
Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA
PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )
13 Apr 2022
ASCO GU 2022: Latest in mHSPC
Prof Eleni Efstathiou, Prof Karim Fizazi, Prof Kim Chi and Prof Matthew Smith
ASCO GU 2022: Latest in mHSPC ( Prof Eleni Efstathiou, Prof Karim Fizazi, Prof Kim Chi and Prof Matthew Smith )
8 Mar 2022
ASCO GU 2022: PARP inhibitors in prostate and MAGNITUDE
Dr Neal Shore and Prof Kim Chi
ASCO GU 2022: PARP inhibitors in prostate and MAGNITUDE ( Dr Neal Shore and Prof Kim Chi )
4 Mar 2022
An AI-derived digital pathology-based biomarker to predict the benefit of ADT in...
Prof Daniel Spratt - University Hospitals Seidman Cancer Center, Cleveland, USA
An AI-derived digital pathology-based biomarker to predict the benefit of ADT in PC with validation in NRG/RTOG 9408 ( Prof Daniel Spratt - University Hospitals Seidman Cancer Center, Cleveland, USA )
3 Mar 2022
SG in combination with pembro in patients with mUC who progressed after platinum...
Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA
SG in combination with pembro in patients with mUC who progressed after platinum (PLT)-based regimens ( Dr Petros Grivas - Seattle Cancer Care Alliance, Seattle, USA )
28 Feb 2022
NMIBC treated with IL-15RαFc superagonist N-803 and BCG infusion
Prof Sam Chang - Vanderbilt University School of Medicine, Nashville, USA
NMIBC treated with IL-15RαFc superagonist N-803 and BCG infusion ( Prof Sam Chang - Vanderbilt University School of Medicine, Nashville, USA )
28 Feb 2022

More from ecancer

Stay up to date with our ecancer newsletter

Learn more

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

Learn more

Support ecancer's work by making a donation